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ABSTRACT:
Antipyrine is a useful probe to evaluate variation of in vivo activities
of oxidative hepatic drug-metabolizing enzymes. Here we describe
a new approach using 13C labeling and NMR spectroscopy for the
direct and simultaneous detection of all phase I and phase II
metabolites of antipyrine in rat urine. [C-methyl-13C]Antipyrine was
synthesized and administered orally to rats (100 mg/kg), and the 0-
to 24-h postdose urine was analyzed by 100-MHz 13C NMR spec-
troscopy under the conditions of distortionless enhancement by
polarization transfer without any pretreatments such as deconju-
gation, chromatographic separation, and solvent extraction. Con-
sequently, all the major metabolites in urine were successfully
detected with favorable signal-to-noise ratios in the limited acqui-
sition time (30 min). The assignments of the resonances were
performed by enzymic modification and spiking authentic samples.
The reproducibility of the NMR detection was sufficient for the
quantitative evaluation of the metabolic profile. Effects of 3-meth-
ylcholanthrene on antipyrine metabolism were examined by this
approach to evaluate variation of in vivo phase I and phase II
metabolism of antipyrine in rats. The present approach is useful
and practical to evaluate variation of in vivo activities of conjuga-
tion enzymes as well as oxidation enzymes responsible for the
formation of antipyrine metabolites in rats. This direct approach
would enhance the value of the antipyrine test because of the
simplicity and convenience.
Antipyrine, one of the antipyretic and analgesic drugs, has been
extensively used as a probe to study the influence of age, diseases,
drugs, heredity, and environmental factors on oxidative hepatic drug-
metabolizing capacity (St Peter and Awni, 1991; Hartleb, 1991).
Antipyrine is metabolized by several forms of cytochrome P-450
(Sharer and Wrighton, 1996), and the resulting oxidative metabolites
are extensively conjugated and excreted in urine of both humans
(Bassmann et al., 1985; Palette et al., 1991; Moreau et al., 1992) and
rats (Velic et al., 1995). The main oxidative metabolites in humans are
3-hydroxymethylantipyrine (HMA)1, 4-hydroxyantipyrine (OHA),
and norantipyrine (NORA) (Fig. 1). The main oxidative metabolites in
rats are these three metabolites and 4,49-dihydroxyantipyrine
(DOHA). Whereas glucuronide conjugation is the major phase II
pathway in humans, sulfoconjugation is prominent in rats (Bottcher et
al., 1982b).
The quantitation of antipyrine and its metabolites excreted in urine
has been used to understand the variation of the oxidative hepatic
drug-metabolizing capacity (Buters and Reichen, 1990; Groen et al.,
1992; Anadon et al., 1995; Ali et al., 1995; Yang et al., 1996). A
number of methods using HPLC have been reported for the determi-
nation of antipyrine and its metabolites (Danhof et al., 1979a; Eich-
elbaum et al., 1981; Teunissen et al., 1983a; Bassmann et al., 1985;
Mikati et al., 1988; Palette et al., 1991; Velic et al., 1995). However,
the direct and simultaneous determination of all phase I and phase II
metabolites in biological materials has not been reported, except a
1 Abbreviations used are: HMA, 3-hydroxymethylantipyrine; DEPT, distortion-
less enhancement by polarization transfer; MS, mass spectra; 3-MC, 3-methyl-
cholanthrene; HMA-G, 3-hydroxymethylantipyrine glucuronide; NORA, noran-
tipyrine; NORA-S, norantipyrine sulfate; NORA-G, norantipyrine glucuronide;
OHA, 4-hydroxyantipyrine; OHA-S, 4-hydroxyantipyrine sulfate; OHA-G, 4-hy-
droxyantipyrine glucuronide; DOHA, 4,49-dihydroxyantipyrine; DOHA-S, 4,49-di-
hydroxyantipyrine sulfate; HM-NORA, 3-hydroxymethyl-norantipyrine; I.S., inter-
nal standard.
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FIG. 1. Structures of antipyrine and oxidative metabolites.
p, labeled position.
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radio-HPLC method (Velic et al., 1995) that is troublesome to use and
unsuitable for the application to humans because of the radiation
hazard. Enzymic or chemical deconjugation followed by HPLC anal-
ysis is still the standard approach; this causes analytical problems due
to the lability of NORA, OHA, and DOHA liberated after the decon-
jugation (Danhof et al., 1979a; Bottcher et al., 1982a, 1984; Teunissen
et al., 1983a; Palette et al., 1991), variable susceptibility of individual
metabolites to deconjugation (Bottcher et al., 1982a,b, 1984; Teunis-
sen et al., 1983a; Moreau et al., 1992), and the volatility of NORA
during desiccation (Teunissen et al., 1983a). Thus studies of anti-
pyrine metabolism are still hampered by the lack of a convenient
determination method.
The usefulness of the stable isotope tracer technique using13C
labeling of substrates followed by NMR spectroscopy of biofluids has
become accepted in metabolic investigations (London 1988; Simpson
1991; Malet-Martino and Martino, 1992). Owing to the high speci-
ficity of detection, the application of the tracer technique enables
analysis of biological fluids without resorting to extraction and chro-
matographic separations. Therefore, the technique saves much time
and analytical effort, and the decomposition and loss of compounds
can be minimized. We have demonstrated the usefulness of the NMR
approach with13C labeling (approximately 100% enrichment) for
pharmacokinetic research in terms of sensitivity and specificity (Baba
et al., 1990, 1995; Akira et al., 1993, 1997a, 1998; Akira and Shino-
hara, 1996). In the present study, the NMR approach with13C labeling
has been presented for the direct detection of all phase I and phase II
metabolites that occur in rat urine after oral dosing with [13C]an-
tipyrine.
Materials and Methods
Chemicals and Reagents.[4-13C]Ethyl acetoacetate (99 atom %13C) was
purchased from Nippon Sanso (Tokyo, Japan). Ethyl acetoacetate was pur-
chased from Tokyo Kasei Kogyo (Tokyo, Japan). OHA was purchased from
Aldrich (Tokyo, Japan). Chlorosulfonic acid,N-bromosuccinimide, and silica
gel (Wakogel C-300) were purchased from Wako Pure Chemical Industries
(Osaka, Japan). HMA was synthesized according to the method reported by
Buijs et al. (1986).b-Glucuronidase (bovine liver, 114 U/g) was purchased
from Funakoshi (Tokyo, Japan). Antipyrine, NORA, and other reagents were
purchased from Kanto Chemical (Tokyo, Japan).
Instrumentation. 1H NMR and1H-decoupled13C (13C{1H}) NMR spectra
of compounds synthesized or isolated from urine were measured in chloro-
form-d1 or methanol-d4 on Varian (Tokyo, Japan) GEMINI300 or Bruker
(Tsukuba, Japan) DPX400 spectrometers, and chemical shifts were referenced
to those of chloroform (d1H 7.26 andd13C 77.0) and methanol (d1H 3.35 and
d13C 49.0). Mass spectra (MS) were recorded on a ThermoQuest (San Jose,
CA) TSQ7000 spectrometer. Melting points were determined on a Yanako
(Kyoto, Japan) MP-S3 apparatus and were uncorrected. The isotopic purity of
13C-labeled compounds was estimated on the basis of the ion intensities in the
region of the molecular ion on MS.
Isolation of DOHA sulfate (DOHA-S) from urine was performed using an
HPLC system equipped with Inertsil PREP-ODS column (2503 30 mm i.d.,
10mm; GL Sciences, Tokyo, Japan) with a precolumn, as described previously
(Akira et al., 1997b), except for UV detection at 243 nm and the mobile phase
made up from solvent A, methanol/0.5% acetic acid in H2O (1:1, v/v), and
solvent B, methanol. Metabolites were completely eluted within 30 min using
the following linear gradient: 0 min: 20% B; 30 min: 80% B.
13C NMR spectra of urine samples were measured at 300 K on a Bruker
DPX400 spectrometer using a 5-mm i.d. NMR tube, under the usual1H-
decoupling conditions (13C{1H}) or the conditions of distortionless enhance-
ment by polarization transfer (DEPT) with1H decoupling (Morris, 1984).
Parameters were spectral width, 26178 Hz; time domain points, 65536; pulse
width 6.3 ms (80° pulse); acquisition time, 1.25 s; recycle time, 3.25 s; zero
filling; and line broadening, 1.0 Hz. The flip angle of theu pulse was set at 45°
in the DEPT experiments unless otherwise stated. The total accumulation time
was 30 min in all experiments. The13C chemical shifts were referenced to that
of sodium 3-trimethylsilyl[2,2,3,3-2H4]propionate (d
13C 0).
Synthesis of13C-Labeled Compounds.The following synthetic steps were
investigated using unlabeled compounds, and the structures were confirmed by
the 1H NMR spectroscopy before the syntheses of labeled compounds.
[C-methyl-13C]NORA was prepared by refluxing a solution of [4-13C]ethyl
acetoacetate (2.0 g) and phenylhydrazine (1.65 ml) in 20 ml of H2O/ethanol
(1:1, v/v). The compound was obtained as a yellow solid after purification by
flash column chromatography over 60 g of silica gel with chloroform/methanol
(400:1, v/v) as the eluent (2.59 g; 97% based on ethyl acetoacetate;.99 atom
% 13C); m.p. 126.4–127.2°C;1H NMR (chloroform-d1) d
1H 2.19 (3H, d,J 5
129.0 Hz, C-methyl), 3.43 (2H, s, methylene), 7.16 to 7.86 (5H, aromatic
protons);13C{1H}NMR (chloroform-d1) d
13C 17.0 (C-methyl); MS (EI):m/z
175 (M1, 100%), 105 (23%), 91 (47%), 77 (51%). Anal Calcd. for
C9
13C1H10N2O: C, 68.56; H, 5.75; N, 15.99. Found: C, 68.46; H, 5.84; N,
15.94.
[C-methyl-13C]Antipyrine was synthesized by methylation of [C-methyl-
13C]NORA (2.53 g) with iodomethane according to the method described by
Huetter et al. (1987). The compound was obtained as a white powder (1.78 g)
after purification by flash column chromatography over 150 g of silica gel with
chloroform/methanol (100:1, v/v) as the eluent. The subsequent recrystalliza-
tion gave crystalline white powder (1.37 g; 50% based on NORA;.99 atom
% 13C); m.p. 109.9–111.4°C (from hexane/ethanol (20:1);1H NMR (chloro-
form-d1) d
1H 2.23 (3H, dd,J 5 129.2 and 0.85 Hz, C-methyl), 3.06 (3H, s,
N-methyl), 5.40 (1H, m, methine), 7.26 to 7.45 (5H, aromatic protons);
13C{1H}NMR (chloroform-d1) d
13C 13.2 (C-methyl); MS (EI):m/z 189 (M1,
60%), 97 (88%), 77 (100%), 57 (83%). Anal Calcd. for C10
13C1H12N2O: C,
69.82; H, 6.39; N, 14.80. Found: C, 70.03; H, 6.54; N, 14.81.
[C-methyl-13C]OHA was synthesized according to the method reported by
Pschorr (1896). Briefly, [C-methyl-13C]antipyrine (102 mg) was converted to
4-bromo-[C-methyl-13C]antipyrine by the reaction with equimolar amount of
N-bromosuccinimide, and then the brominated compound was hydrolyzed by
potassium hydroxide. [C-methyl-13C]OHA was obtained as a white solid after
purification by silica gel column chromatography with chloroform/methanol
(200:1, v/v) as the eluent (14.5 mg; 14% based on antipyrine;.99 atom %
13C); m.p. 179.6–181.2°C;1H NMR (methanol-d4) d
1H 2.25 (3H, d,J 5 129.3
Hz, C-methyl), 2.95 (3H, s,N-methyl), 4.61 (1H, s, OH), 7.37 to 7.56 (5H,
aromatic protons);13C{1H}NMR (methanol-d4) d
13C 9.20 (C-methyl); MS
(EI): m/z 205 (M1, 8%), 77(12%), 57 (100%). Anal Calcd. for
C10
13C1H12N2O2 z 1/5H2O: C, 63.27; H, 5.98; N, 13.41. Found: C, 63.16 H,
6.19 N, 13.16.
Synthesis of OHA Sulfate (OHA-S).To a solution of OHA (0.31 g) in 21
ml of dehydrated pyridine was added dropwise chlorosulfonic acid (200ml),
keeping the temperature below 10°C by an ice-water bath followed by stirring
for 50 h at room temperature. The reaction mixture was neutralized with 3.2%
sodium hydroxide in methanol (about 9 ml), and evaporated to dryness. The
oily residue was washed with 100 ml of diethyl ether, dissolved in 20 ml of
ethanol, and the undissolved material was filtered off. The filtrate was mixed
with 120 ml of diethyl ether, and the resulting precipitate was collected by
filtration and dried in vacuo to give sodium salt of the title compound as a
pale yellow crystalline powder (90 mg; 17%); m.p. 138.3–139.3°C; MS
(FAB2): m/z 283 ([M-Na]2, 100%), 203 (28%). Anal Calcd. for
C11H11N2NaO5S z 2H2O: C, 38.60; H, 4.42; N, 8.18. Found: C, 38.87; H, 4.39;
N, 7.97. 1H NMR (methanol-d4) d
1H 2.39 (3H, s, C-methyl), 3.15 (3H, s,
N-methyl), 7.41 to 7.57 (5H, aromatic protons).
Animal Experiments and Sample Treatments.Male Wistar rats (185–220
g) were used. Five rats were orally administered with [13C]antipyrine (100
mg/kg) dissolved in saline (10 mg/ml), and two rats were administered with
[13C]NORA (100 mg/kg) suspended in olive oil (10 mg/ml) after an overnight
fast (for 18 h). In addition, four rats were treated for three consecutive days
with 3-methylcholanthrene (3-MC) suspended in olive oil, 30 mg/kg i.p., and
then administered with [13C]antipyrine in the same manner as shown above.
Rats were placed in individual metabolic cages. Urine that was collected before
administration of antipyrine and at 0- to 24- and 24- to 48-h postdose was held
below 5°C by an ice-water bath. The metabolic cage was washed with distilled
water to completely recover the antipyrine metabolites. Urine (5–15 ml) and
the cage wash collected from each rat were combined, and the solution was
diluted to 15 to 30 ml with distilled water after filtration, and then stored at
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220°C until analyzed. During the experiments the animals had free access to
tap water. They were allowed free access to food at 3 h after the administration.
The urine sample was subjected to the following analysis without concentra-
tion or after concentrated by a factor of 3 using freeze-drying. An aliquot (0.5
ml) of the urine sample was mixed with 50ml of a solution of [2-13C]sodium
acetate internal standard (I.S.) in deuterium oxide (4.036 mg/ml). Deuterium
oxide was used for field-frequency lock. The mixture was centrifuged (2500
rpm, 5 min), and the supernatant was analyzed by13C NMR spectroscopy. The
ratios of resonance integral intensities of the metabolites to that of the I.S. were
calculated, and then corrected by the degree of concentration (1 or 3) and the
total volume of the urine sample: integral intensity ratio3 1/degree of
concentration3 urine volume/0.5.
Isolation of [C-methyl-13C]DOHA-S from Urine. Male Wistar rats were
orally administered with [13C]antipyrine as described above. Urine samples
collected over a 0- to 24-h interval from four rats (;40 ml) were incubated
with b-glucuronidase (30 mg protein) at 37°C for 3 h to eliminate glucu-
ronidated metabolites of antipyrine. The treated urine was washed with chlo-
roform (100 ml 3 2) to eliminate less polar phase I metabolites, and the
aqueous fraction was applied as 8-ml aliquots to five pretreated Sep-Pak C18
cartridges (Waters Associates, Milford, MA). The cartridges were washed with
5 ml of 0.5% acetic acid in water followed by elution with 20 ml of methanol/
0.5% acetic acid in H2O (20:80, v/v). All the eluates were combined and
concentrated by a rotary evaporator below 30°C, and then freeze dried. The
residue was reconstituted in methanol (0.5 ml), and 20- to 50-ml portions of the
solution were injected onto the HPLC column. Three major peaks due to
sulfated metabolites of antipyrine were observed at 13, 16 (OHA-S), and 20
min after injection. The peak at 13 min was presumed to be due to DOHA-S,
judging from the elution order of antipyrine metabolites reported by Velic et al.
(1995). The eluates corresponding to the peak at 13 min were collected,
evaporated by a rotary evaporator, and then subjected to freeze drying to give
DOHA-S as a yellow oil (3 mg);1H NMR (methanol-d4) d
1H 2.27 (3H, d,J 5
129.7 Hz, C-methyl), 3.05 (3H, s,N-methyl), 6.96 (2H, d,J 5 8.75 Hz,
aromatic protons), 7.23 (2H, d,J 5 8.75 Hz, aromatic protons);13C{1H}NMR
(methanol-d4) d
13C 9.91 (C-methyl); MS (FAB-): m/z 300 (M2, 100%), 220
(26%).
Enzymic Modification of Urine Samples.To identify conjugated metab-
olites of antipyrine, 0.5 ml of the 0- to 24-h postdose urine was transferred to
an NMR tube after being mixed with 50ml of deuterium oxide, incubated at
37°C with or withoutb-glucuronidase (5 mg-protein), and then analyzed by
13C NMR spectroscopy without additional treatment.
Results and Discussion
When the NMR approach with13C labeling is applied to drug
metabolism studies, the labeled position has to be selected to get
sufficient spectral resolution and sensitivity. As antipyrine is metab-
olized as shown in Fig. 1, the C3, C4, and C-methyl positions are
favorable for labeling in terms of spectral resolution. In the proton-
decoupling conditions, the intensities of13C resonances from proton-
ated carbons are significantly increased due to the nuclear Overhauser
enhancement (NOE, maximum 1.99). Also the resonances of proton-
ated carbons are usually more intense than those of nonprotonated
carbons due to the short spin-lattice relaxation time (T1), which allows
the accumulation of more scans within a limited acquisition time.
Therefore, protonated carbons (C-methyl and C4) are generally pref-
erable for labeling (Akira et al., 1993; Baba et al., 1995). The
C-methyl of the carbon of the parent drug retains at least two protons
in all metabolite species, whereas the C4 is a quaternary carbon in
OHA and DOHA. Thus the C-methyl was considered most suitable
for labeling in terms of both spectral resolution and sensitivity. Thus,
[C-methyl-13C]antipyrine with high incorporation level (.99%) was
synthesized from [4-13C]ethyl acetoacetate in two steps.
The labeled antipyrine was orally administered to rats and the
excreted urine was analyzed by13C NMR. The signal-to-noise ratios
of the DEPT spectra were enhanced by a factor of 2- to 3-fold,
compared with those of the13C{1H}-NMR spectra in the same accu-
mulation time (Morris, 1984). All of the resonances observed in the
13C{1H}-NMR spectra, except that of;1% natural abundance of
urea, were also observed in the DEPT spectra. Thus, the following
NMR spectra were all obtained by the DEPT experiments. In the 0- to
24-h postdose urine, six resonances due to the major metabolites of
antipyrine were observed atd13C 64.4, 57.8, 16.1, 12.0, 11.9, and 11.8
with an antipyrine resonance atd13C 14.3, as shown in Fig. 2B. Three
resonances due to the minor metabolites of antipyrine were also
observed atd13C 60.6, 16.0, and 11.7. The 24- to 48-h postdose urine
gave no significant13C resonance due to antipyrine and its metabo-
lites, which showed the 0- to 24-h urine collection was sufficient to
obtain the total metabolic pattern of antipyrine. In rats, antipyrine is
mainly biotransformed to HMA, HMA glucuronide (HMA-G),
NORA sulfate (NORA-S), OHA-S, DOHA-S, and OHA glucuronide
(OHA-G), and these metabolites are excreted in urine with a small
amount of antipyrine (Velic et al., 1995). Thus, the major resonances
in the methylene region (d13C 64.4, and 57.8) were considered to be
due to HMA and its glucuronide, whereas the major resonances in the
methyl region (d13C 16.1, 12.0, 11.9, and 11.8) due to NORA-S,
OHA-S, DOHA-S, and OHA-G. This presumption was found to be
correct by the DEPT experiments (u pulse, 135°) of the urine sample.
The resonances atd13C 57.8, 12.0, and 11.9 were assigned to HMA,
OHA-S, and DOHA-S, respectively, by spiking those authentic sam-
FIG. 2. 13C NMR spectra of control urine (A), 0- to 24-h urine from a rat dosed
with [13C]antipyrine (100 mg/kg p.o.) (B), and 0–24 h postdose urine incubated
with b-glucuronidase at 37°C for 3 h (C).
Key: 1 5 HMA-G; 2 5 HM-NORA (tentative); 35 HMA; 4 5 I.S.; 5 5
NORA-S; 6 5 NORA-G; 7 5 antipyrine; 85 OHA-S; 9 5 DOHA-S; 10 5
OHA-G; 11 5 OHA.
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ples. Thus, the other major resonance (d13C 64.4) in the methylene
region was assigned to HMA-G.
The postdose urine was incubated withb-glucuronidase to assign
the remaining major resonances atd13C 16.1 and 11.8. Consequently,
the resonances at 64.4 (HMA-G), 16.0, 11.8, and 11.7 disappeared
with concurrent increase of the resonances atd13C 57.8 (HMA), 11.2,
and 11.1, as shown in Fig. 2C. In the control experiments, the NMR
spectrum showed no apparent change, showing the resonances atd13C
64.4, 16.0, 11.8, and 11.7 to be all glucuronide conjugates. The
resonance atd13C 11.2 was assigned to OHA by spiking the labeled
authentic compound. Thus the major resonance atd13C 11.8 was
assigned to OHA-G, and the remaining major resonance atd13C 16.1
in the methyl region, that was unaffected by-glucuronidase, was
assigned to NORA-S from the metabolic pattern of antipyrine de-
scribed above.
To confirm the assignment of NORA-S, [13C]NORA was orally
administered to rats, and the postdose urine was analyzed by13C
NMR. As shown in Fig. 3, two major resonances due to metabolites
of NORA were observed atd13C 16.1 and 16.0. Bottcher et al. (1985)
have reported that NORA is completely conjugated to form NORA-S
and NORA glucuronide (NORA-G) in rats. The resonances atd13C
16.1 and 16.0 were assigned to NORA-S and NORA-G, respectively,
because only the resonance atd13C 16.0 disappeared by theb-glucu-
ronidase treatment. These resonances were greatly shifted downfield
compared with those due to C-methyl groups of other antipyrine
metabolites, probably due to the characteristic ring structure (Palette
et al., 1994). From these experimental results, the above-mentioned
assignment of NORA-S was confirmed. Also, the minor glucu-
ronidated metabolite (d13C 16.0) in Fig. 2B was identified to be
NORA-G. The NMR spectrum showed a resonance atd13C 60.6 due
to a minor metabolite of NORA, which was also observed in Fig. 2B.
The resonance was found to be due to a methylene group by the DEPT
experiments (u pulse, 135°). Thus, this resonance was tentatively
assigned to 3-hydroxymethyl-norantipyrine (HM-NORA, see Fig. 1),
recently reported as a minor urinary metabolite of antipyrine in rats
(Velic et al., 1995).
All the antipyrine metabolites reported to occur in rat urine were
identified on the13C NMR spectra by the above experiments. The
minor metabolite, NORA-G, was also shown to occur in rats, which
has been previously unreported. The results showed that all of the
major antipyrine metabolites in rats could be directly detected in one
operation without any pretreatments such as extraction, chromatogra-
phy, and deconjugation by the combined use of13C NMR and13C
labeling of the C-methyl carbon.
The signal-to-noise ratios of the major metabolites, obtained using
the limited acquisition time (30 min), were considered sufficient for
the quantitative evaluation of the metabolic profile. The analysis of
the postdose urine in Fig. 2B was repeated 6 times to examine the
reproducibility of the NMR detection. Consequently, the coefficients
of variation (%) of the integral intensity ratios between the metabo-
lites and the I.S. were as follows: HMA-G, 6.9; HMA, 1.8; NORA-S,
1.1; AP, 7.3; OHA-S, 2.0; DOHA-S, 3.0; OHA-G, 2.0. In the HPLC
analyses of antipyrine metabolites, attention has to be paid to the
lability of OHA, DOHA, and NORA liberated after the deconjugation
(Danhof et al., 1979a; Bottcher et al., 1982a, 1984; Teunissen et al.,
1983a; Palette et al., 1991). However, the NMR approach directly
detects their chemically stable conjugates (Teunissen et al., 1983a;
Bottcher et al., 1984; Palette et al., 1993) in urine, so that accurate and
reliable results are obtained. To compare the urinary excreted amounts
n the individual rats, the ratios of resonance integral intensities
between the metabolites and the I.S. were calculated and corrected as
shown in the experimental section (Table 1). These integral ratios
r flect the metabolic profile of antipyrine. It should be noted that
relative integrations do not represent molar ratios between the metab-
olites because the NMR sensitivity for the individual metabolites,
which is influenced by the different NOE andT1 of detected nucleus,
differs from one to another (Akira et al., 1993).
he application of13C NMR to investigating alterations in the
metabolism of antipyrine was examined in the case of 3-MC induc-
tion. The spectra of the 0- to 24-h postdose urine from 3-MC-treated
rats were markedly different from those from normal rats, as shown in
Fig. 4. The excretion of NORA-G, OHA-G, and OHA-S increased by
FIG. 3. 13C NMR spectrum of 0- to 24-h urine from a rat dosed with [13C]NORA (100 mg/kg p.o.).
Key: as in Fig. 2.
1251DIRECT DETECTION OF ANTIPYRINE METABOLITES BY NMR
the induction, whereas that of HMA and HMA-G decreased, as shown
in Table 1. The excretion of NORA-S and DOHA-S did not change.
The increase in OHA (sulfated1 glucuronidated) excretion and the
decrease in HMA (free1 conjugated) excretion have been reported in
3-MC-treated rats (Danhof et al., 1979b; Nakagawa et al., 1983;
Teunissen et al., 1983b), which are consistent with our results.
The effects of 3-MC pretreatment on the metabolic formation of
NORA is inconsistent across the literature. Teunissen et al. (1983b)
have reported a decrease in NORA (sulfated) excretion by the induc-
tion, whereas Danhof et al. (1979b) and Nakagawa et al. (1983)
reported no change in the excretion. The lability of NORA, liberated
after the deconjugation procedures for the HPLC analysis in these
reports, may be responsible for this discrepancy. In addition, Bottcher
et al. (1984) have directly measured urinary NORA conjugates by
thin-layer chromatography coupled with radioisotope tracer tech-
niques, where urine is treated with urease and extracted with metha-
nol. They reported that NORA-S excretion is significantly enhanced
by 3-MC induction, and NORA-G is not excreted in urine of both
control and 3-MC-treated rats. On the contrary, our results showed no
change in NORA-S excretion, and a significant increase in NORA-G
excretion and in the total excretion of NORA-S and NORA-G, which
are in conflict with the above-mentioned results by other researchers.
It should be noted that the 3-MC induction of glucuronidation in
antipyrine metabolism was first shown by the detection of significant
NORA-G excretion. This contradiction may be due to the difference
of strain, age, and body weight of the rats, administration route, and
induction method. Our experimental results are, in any event, consid-
ered to be most reliable because the NMR approach involves no
pretreatments such as deconjugation and solvent extraction.
In conclusion, the13C NMR approach using13C-labeling has been
demonstrated to be useful and practical for the direct and simulta-
neous detection of all phase I and phase II metabolites in rat urine. The
approach saves time and effort in data acquisition because of the need
for little pretreatment of samples and the ability to accommodate
relatively short accumulation times. The present approach is useful to
evaluate variation of in vivo activities of conjugation enzymes as well
as oxidation enzymes responsible for the formation of antipyrine
metabolites in the rat. As the metabolic pattern of antipyrine in
humans is similar to that in rats, the NMR approach would be also
applicable to humans. It is hoped that the introduction of this direct
assay may enhance the value of antipyrine test (Hartleb, 1991) in
biochemical and clinical pharmacological research because of the
simplicity and convenience.
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